Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Finished

SweetCancerTest Diagnostics of aberrant cancer glycosylation signatures

Coordinator
Tel Aviv University, Israel
Runs
1 July 2022 to 31 December 2023
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069379

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is a leading cause of death worldwide and novel diagnostic and therapeutic approaches are much needed. All living cells are covered with a dense layer of sugar-coat that is altered in cancer. One of the hallmarks of cancer is the expression of aberrant cell surface glycosylation patterns compared to normal cells. Current antibody-based assays against cancer glycans are commonly utilized to monitor clinical response to therapy, however none is useful for early detection or diagnosis due to low sensitivity and specificity.

We aim to develop cancer diagnostics based on signatures of carbohydrate-neoantigens. We developed a unique system to generate potent antibodies of high specificity and affinity against various cancer glycans. Such potent antibodies that recognize tumor-associated carbohydrate-neoantigens can potentially be used as novel cancer diagnostics. Such validated tools could be used to identify cancer at an early stage and also for optimizing therapy to patients of unique sugar-code signatures.

Topics

Who is involved

OrganisationCityCountryRole
Tel Aviv UniversityTel AvivIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI